Hepatitis Drugs Market Report – Forecast to 2023
- December, 2016
- Domain: Healthcare - Pharmaceuticals
- Get Free 10% Customization in this Report
Hepatitis is a medical condition where the liver is predominantly affected, further infecting the digestive system and brain in long term. There are three major types of hepatitis condition – HAV, HBV, and HCV. HCV is a major public health problem where liver gets inflamed due to infection. Certain drugs, toxins, heavy alcohol use, bacterial and viral infections can cause hepatitis infection.
Hepatitis C infection can bring both acute and chronic hepatitis disease. Approximately, 80% of the patients get chronically infected with Hepatitis C disease. Hepatitis C Virus (HCV) spreads through the blood of an infected individual by the use of shared needles or supplies used to infuse drugs. Vaccines are available only for Hepatitis A and Hepatitis B viruses. Research into the development of a vaccine for Hepatitis C is under way.
Factors such as rise in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.
The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.
The “Global Hepatitis Drugs Market” is estimated to witness a CAGR of 15.0% during the forecast period 2017–2023. The Hepatitis Drugs market is analyzed based on two segments – conditions and regions.
The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the hepatitis drugs market growth followed by Europe. The Asia Pacific and RoW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various HBV and HCV drugs are expected to increase in the coming years.
Therapeutic Application Analysis:
The most common hepatitis being viral hepatitis can be caused by either of the five hepatotropic viruses, namely Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Hepatitis E. The non-viral hepatitis can be caused by autoimmune diseases, alcohol, few of prescription medications, and toxic substances. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future HBV and HCV drugs to be commercially available in the market. The advent of interferon-free combination regimens and DAAs is one of the major drivers for the global hepatitis drugs market, specifically for the HCV market. Moreover, various IFN-regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause lesser side effects than currently approved therapies. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the Global Hepatitis Drugs market.
Gilead Sciences Inc., Abbvie Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Vertex Pharmaceuticals Inc., Novartis AG, Hoffmann-La Roche Ltd., and other predominate & niche players.
At present, the HCV drugs are dominating the Global Hepatitis Drugs market – but, a lot of new players are focusing on developing HBV drug molecules to gain future business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of hepatitis molecules and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.
The report provides complete details about the usage and adoption rate of hepatitis drugs in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the hepatitis drugs adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
1 Industry Outlook
1.1 Industry Overview
1.2 Industry Trends
1.3 PEST Analysis
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Total Addressable Market (TAM)
3.2 Disease Overview
3.2.1 Hepatitis A
3.2.2 Hepatitis B
3.2.3 Hepatitis C
3.2.4 Hepatitis D
3.2.5 Hepatitis E
3.3 Disease Transmission
3.4 Related Markets
4 Market Outlook
4.2 Regulatory Bodies & Standards
4.3 Porter 5 (Five) Forces
5 Market Characteristics
5.3 Market Dynamics
126.96.36.199 Increasing demand for hepatitis drugs
188.8.131.52 Focus on advanced DAAs
184.108.40.206 Introduction of IFN-free therapies
220.127.116.11 Growth of injection drug users
18.104.22.168 Long approval process and stringent regulations
22.214.171.124 Side effects of hepatitis drugs
126.96.36.199 Increase in the number of generic drugs
188.8.131.52 Increasing market competition
184.108.40.206 Significant increase in mergers & acquisitions
220.127.116.11 Emergence of combination drugs
18.104.22.168 Preventive healthcare
22.214.171.124 Focus of companies on emerging market
5.3.4 DRO – Impact Analysis
6 Trends, Roadmap, and Projects
6.1 Market Trends & Impact
6.2 Technology Roadmap
7 Types: Market Size and Analysis
7.2 Hepatitis A Segment
7.3 Hepatitis B Segment
7.4 Hepatitis C Segment
8 Trending Hepatitis Drugs
8.1.11 Intron A
9 Regions: Market Size and Analysis
9.2 Global Hepatitis Drugs Market by Geographical Segmentation
10 Vendor Scenario
10.1 Market Share Ranking: 2016
10.1.1 Gilead Sciences Inc.
10.1.1.1 Sovaldi (sofosbuvir)
10.1.1.2 Harvoni (ledipasvir and sofosbuvir)
10.1.1.3 Viread (tenofovir disoproxil fumarate)
10.1.1.4 Hepsera (adefovir dipivoxil)
10.1.2 AbbVie Inc.
10.1.2.1 Viekira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir)
10.1.3 Johnson & Johnson
10.1.3.1 Olysio (simeprevir)
10.1.3.2 Incivo (telaprevir)
10.1.4 Merck & Co. Inc.
10.1.4.1 Zepatier (elbasvir and grazoprevir)
10.1.4.2 Victrelis (boceprevir)
10.1.4.3 Peg-Intron (peginterferon alfa-2b)
10.1.4.4 Rebetol (ribavirin)
10.1.4.5 Intron A (interferon alfa-2b, recombinant)
10.1.5 GlaxoSmithKline plc
10.1.5.1 Pediarix Vaccine
10.1.5.4 Epivir (lamivudine)
10.1.6 Vertex Pharmaceuticals Inc.
10.1.6.1 Incivek (telaprevir)
10.1.7 Novartis AG
10.1.7.1 Tyzeka (telbivudine)
10.1.8 Hoffmann-La Roche Ltd.
10.1.8.1 Pegasys (peginterferon alfa-2a)
11 Vendor Profiles
11.1.1 Merck & Co. Inc.
126.96.36.199 Business unit
188.8.131.52 Geographic Revenue
184.108.40.206 Recent developments
220.127.116.11 SWOT Analysis
18.104.22.168 Business Strategies
11.1.2 Hoffmann-La Roche Ltd.
22.214.171.124 Business Unit
126.96.36.199 Geographic revenue
188.8.131.52 Recent developments
184.108.40.206 SWOT analysis
220.127.116.11 Business strategies
11.1.3 Gilead Sciences
18.104.22.168 Business Unit
22.214.171.124 Geographic revenue
126.96.36.199 Recent developments
188.8.131.52 SWOT analysis
184.108.40.206 Business strategies
11.1.4 Novartis AG
220.127.116.11 Business Unit
18.104.22.168 Geographic revenue
22.214.171.124 Recent developments
126.96.36.199 SWOT analysis
188.8.131.52 Business strategies
11.1.5 GlaxoSmithKline plc
184.108.40.206 Business Unit
220.127.116.11 Geographic revenue
18.104.22.168 Recent developments
22.214.171.124 SWOT analysis
126.96.36.199 Business strategies
12 Global Generalist
12.1 Vertex Pharmaceuticals Inc.
188.8.131.52 Recent developments
12.1.2 Vertex Pharmaceuticals Inc. in 2015
12.2 Johnson & Johnson
184.108.40.206 Recent developments
12.2.2 Johnson & Johnson in 2015
13 Market Landscape
13.1 Market Landscape
13.1.1 Mergers & Acquisitions (M&A)
TABLE 1 MAJOR HEPATITIS A DRUGS 15
TABLE 2 MAJOR HEPATTIS B DRUGS 16
TABLE 3 MAJOR HEPATITIS C DRUGS 18
TABLE 4 DISEASE TRANSMISSIONS OF DIFFERENT TYPES OF HEPATITIS 19
TABLE 5 GLOBAL HEPATITIS DRUGS MARKET REVENUE BY TYPE, 2016-2023 ($BILLION) 33
TABLE 6 TRENDING HEPATITIS DRUGS, 2014-2016 ($MILLION) 36
TABLE 7 MERCK & CO. INC.: RECENT DEVELOPMENTS 53
TABLE 8 HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 58
TABLE 9 GILEAD SCIENCES: KEY MEDICINES/PRODUCTS 62
TABLE 10 GILEAD SCIENCES: PIPELINE PRODUCTS 63
TABLE 11 GILEAD SCIENCES: RECENT DEVELOPMENTS 65
TABLE 12 NOVARTIS AG: RECENT DEVELOPMENTS 69
TABLE 13 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 75
TABLE 14 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS 79
TABLE 15 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 82
TABLE 16 MERGER & ACQUISITION, 2014–2015 85
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
Market related information is congregated from both primary and secondary sources.
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.